Burdman J A, Guerra L N, Calabrese M T, Basso A
Department of Endocrinology, Centro de Investigaciones Medicas Albert Einstein, Fundacion CIMAE, Buenos Aires, Argentina.
Neurol Res. 2001 Oct;23(7):721-3. doi: 10.1179/016164101101199234.
Prolactinomas are one of the most frequent tumors of the human anterior pituitary. Dopamine agonists are the choice in the medical treatment of this disease. Bromocriptine (BC) is a well known anti-neoplasic agent in human PRL secreting adenomas although its effect on PRL cells is far from clear. We decided to investigate its influence on cell proliferation parameters: (3H)thymidine incorporation, expression of c-myc and c-fos, and number of estrogen receptors present in the samples. A total of 28 patients were included in this protocol. They were treated with BC (5-7.5mg day(-1) patient(-1)) or with vehicle orally 15 days before surgery. We found that in BC treated patients (3H)thymidine incorporation was lower than in vehicle treated patients. The oncogenes expression were diminished in BC comparing with vehicle-treated patients. No difference in the number of estrogen receptors was observed in the samples from BC or vehicle-treated patients. These results clearly demonstrate that one mechanism to reduce the size of human PRL secreting adenomas by BC is the inhibition of DNA duplication.
催乳素瘤是人类垂体前叶最常见的肿瘤之一。多巴胺激动剂是这种疾病药物治疗的首选。溴隐亭（BC）是治疗人类泌乳素分泌腺瘤的一种知名抗肿瘤药物，尽管其对泌乳素细胞的作用尚不清楚。我们决定研究其对细胞增殖参数的影响：（3H）胸腺嘧啶核苷掺入、c-myc和c-fos的表达以及样本中雌激素受体的数量。本研究共纳入28例患者。在手术前15天，他们接受BC（5 - 7.5mg·日-1·患者-1）治疗或口服赋形剂。我们发现，接受BC治疗的患者中（3H）胸腺嘧啶核苷掺入低于接受赋形剂治疗的患者。与接受赋形剂治疗的患者相比，BC治疗患者的癌基因表达降低。在接受BC或赋形剂治疗患者的样本中，未观察到雌激素受体数量的差异。这些结果清楚地表明，BC缩小人类泌乳素分泌腺瘤大小的一种机制是抑制DNA复制。
